Motor function in Parkinson´s disease during 16h treatment with intravenously (DIZ101), subcutaneously (DIZ102), or intestinally (LCIG) infused levodopa
Objective: To compare the effect of intravenous (DIZ101) and subcutaneous (DIZ102) continuous 16h infusion of a continuously buffered acidic levodopa/carbidopa solution with levodopa/carbidopa intestinal gel…Sex differences in motor response to levodopa in early Parkinson’s disease
Objective: To evaluate differences between males and females in trajectory of motor response to levodopa in early Parkinson’s disease (PD). Background: Previous research has shown…Subanesthetic infusion of ketamine produces long-term reduction in levodopa-induced dyskinesia and depression in individuals with Parkinson’s Disease
Objective: An open-label, dose-finding Phase I/II clinical trial was conducted to test safety and tolerability of low-dose ketamine infusion to treat levodopa-induced dyskinesia (LID), and…Determination of metabotropic glutamate 2 receptor distribution with [3H]-LY-341,495 in hemi-parkinsonian rats with L-DOPA-induced dyskinesia
Objective: To determine the distribution and density of metabotropic glutamate 2 (mGlu2) receptors in the motor loop of the basal ganglia in 6-hydroxydopamine (6-OHDA)-lesioned rats…Can very early levodopa prevent self-injury in Lesch-Nyhan Disease?
Objective: To determine whether levodopa treatment starting at a very young age can prevent the development of the full clinical phenotype in Lesch-Nyhan disease. Background:…Effect of differences in stomach and small intestine pH on response to levodopa in patients with Parkinson’s Disease.
Objective: To examine levels of stomach and small intestine (SI) pH in relation to variable clinical responses to doses of levodopa in Parkinson’s disease (PD)…Levodopa-Entacapone-Carbidopa Intestinal Gel in advanced Parkinson’s disease: a single center experience
Objective: To evaluate the efficacy of Levodopa-Entacapone-Carbidopa Intestinal Gel (LECIG) in achieving adequate control of motor complications in patients with advanced Parkinson’s Disease (APD). Background:…The effect of levodopa on the blood activity of calpains in patients with Parkinson’s disease
Objective: To evaluate the effect of levodopa on the blood activity of calpains in patients with PD Background: Parkinson's disease (PD) is a chronic progressive…Levodopa Pharmacokinetics in Different Levodopa Treatment Regimens plus Opicapone in Parkinson’s Disease Patients with Motor Fluctuations
Objective: This study aims to evaluate the effect of once-daily opicapone (OPC) 50 mg on the pharmacokinetics (PK) of levodopa (LD) in different LD/carbidopa (LD/CD)…Descriptive case studies of patients in their fifth consecutive year of treatment with ND0612
Objective: To describe the long-term experience of three individual patients receiving subcutaneous (SC) levodopa/carbidopa infusion with ND0612 in an open-label clinical safety study. Background: ND0612…
- « Previous Page
- 1
- …
- 15
- 16
- 17
- 18
- 19
- …
- 62
- Next Page »